Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 1;21(2):151-158.
doi: 10.1097/ACI.0000000000000726.

Application of exhaled nitric oxide (FeNO) in pediatric asthma

Maria Di Cicco  1   2 , Diego Giampietro Peroni  1   2 , Vincenzo Ragazzo  3 , Pasquale Comberiati  1   2   4
Affiliations
Review

Application of exhaled nitric oxide (FeNO) in pediatric asthma

Maria Di Cicco et al. Curr Opin Allergy Clin Immunol. .

Abstract

Purpose of review: Fractional concentration of Nitric Oxide in the exhaled air (FeNO) is a moderately good biomarker of type-2 airway inflammation, and its measurement is feasible also in children. The available evidence is still not enough to support the routine use of FeNO to diagnose or manage asthma in every patient in clinical practice. However, its role in identifying asthma with eosinophilic inflammation is of particular interest in the management of severe asthma.

Recent findings: In healthy subjects, FeNO levels increase with age and height, particularly in males, and are also influenced by ethnicity. FeNO measurement can support asthma diagnosis and help in predicting asthma development later in life in young children with recurrent wheezing. FeNO-guided asthma management is effective in reducing asthma exacerbations but may result in a higher daily dose of inhaled corticosteroids. FeNO can also be used as a marker to evaluate adherence to asthma treatment and predict response to different biologicals, especially Omalizumab and Dupilumab.

Summary: This review outlines recent data on the application of FeNO in childhood-onset asthma diagnosis and management, as well as in phenotyping subjects with severe asthma who may benefit from monoclonal antibodies administration.

PubMed Disclaimer

References

    1. O’Connell EJ. The burden of atopy and asthma in children. Allergy 2004; 59: (Suppl 78): 7–11.
    1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5:691–706.
    1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2020. Available at: www.ginasthma.org . Accessed 3 November 2020.
    1. Di Cicco M, D’Elios S, Peroni DG, Comberiati P. The role of atopy in asthma development and persistence. Curr Opin Allergy Clin Immunol 2020; 20:131–137.
    1. Boonpiyathad T, Sözener ZC, Satitsuksanoa P, et al. Immunologic mechanisms in asthma. Semin Immunol 2019; 101333.